Eko Health, an innovator in the use of artificial intelligence (AI) for the early detection of heart and lung diseases, has announced the successful completion of a $41 million Series D financing round.
To date, the company raised over $165 million.
The funding round, with contributions from ARTIS Ventures, Highland Capital Partners, NTTVC, and Questa Capital, will be utilized to enhance both U.S. and global access to Eko Health's advanced early disease detection platform.
About Eko Health
Eko Health is at the forefront of digital health, revolutionizing how healthcare professionals detect and monitor heart and lung diseases. Its portfolio includes digital stethoscopes, patient and provider software, and AI-powered analysis tools.
The FDA-cleared platform, used by over 500,000 healthcare professionals worldwide, allows for earlier and more accurate detection, confident diagnosis, effective treatment management, and superior patient care.
Key Investors and Funding Utilization
The funding round saw participation from ARTIS Ventures, Highland Capital Partners, NTTVC, and Questa Capital.
This substantial financial boost will enable Eko Health to enhance its innovative platform, which combines FDA-cleared algorithms with digital medical devices to support early detection of cardiac and pulmonary diseases during routine physical exams.
Advanced Detection Capabilities
Eko Health’s platform is already in use by over 500,000 healthcare professionals across the U.S. It incorporates sophisticated algorithms to improve the identification and diagnosis of heart and lung conditions.
Notably, the company has recently achieved significant milestones, including U.S. FDA clearances for its structural heart murmur and low ejection fraction (Low EF) detection algorithms.
Clinical Validation
- Heart Murmur Detection: Clinically validated in a Massachusetts General Hospital study, Eko’s murmur detection algorithm was found to double the identification rates of structural heart murmurs compared to conventional practices in primary care.
- Low EF Detection: Developed in collaboration with Mayo Clinic, this algorithm was shown to significantly enhance the identification of heart failure with reduced ejection fraction in GP clinics, according to a study by Imperial College London.
CEO Insights
"Eko harnesses AI to unlock universal access to expert-level cardiac and pulmonary disease detection for patients everywhere," - Connor Landgraf, CEO and co-founder of Eko Health.
He likened Eko’s innovation to the transformation brought by Ring in home security systems, emphasizing that Eko has reinvented the traditional stethoscope into a powerful early disease detection tool.
Addressing a Critical Need
Cardiovascular and pulmonary diseases remain leading causes of death worldwide, highlighting the urgency for early detection tools. Many patients remain unaware of their risk factors due to limited access to effective detection technologies.
Eko Health aims to bridge this gap by integrating its detection capabilities into various physical exams globally, from primary care in the U.S. to maternal-fetal health exams in Nigeria.
Board Chair Perspective
Vas Bailey, PhD, Chair of the Board at Eko Health and Partner at ARTIS Ventures, shared his personal connection to the cause, expressing his commitment to the mission.
"Like countless others, I lost a parent much too early to undetected heart disease. I am deeply inspired by the team's dedication to saving lives by equipping clinicians worldwide with our groundbreaking early detection platform."
Strategic Global Expansion
The new capital will enable Eko Health to deepen its U.S. presence and accelerate expansion into key international markets.
This will be supported by new strategic investments from Double Point Ventures in the U.S., Singapore-based global investor EDBI, and LG Technology Ventures from South Korea.
With these resources, Eko Health is poised to enhance access to its AI-enabled cardiac and pulmonary disease detection platform, ultimately improving patient outcomes on a global scale.
